BioWorld

July 11, 2011

View Archived Issues

BioLineRx Trades IPO for ADR To Access Investors, Partners

New Fentanyl Approvals Hint At Track for Class-Wide REMS

Money Raised By Biotech in 2011

Week in Review

Word on the Street

FDA Approvals in June

Phase I Clinical Trials Update: June 2011

Phase II Clinical Trials Update: June 2011

Phase III Clinical Trials Update: June 2011

American Diabetes Association

American Society of Clinical Oncology

Public Biotechs Drive Funding Increase in H1 2011 v. H1 2010

Biotech companies raised a total of $13.3 billion in the first half of 2011, reclaiming much of the fundraising ground that was lost when the markets crashed in 2008. Read More

Money Raised Year to Date

Non-U.S. Clinical Trials & Regulatory Actions: June 2011

FDA Submissions, Approvals & Other Actions: June 2011

Stock Gainers and Losers For The Week

BioWorld Stock Report For Public Biotechnology Companies

Today's news in brief

BioWorld

BioWorld briefs for July 27, 2026.

Brain-penetrant NLRP3 inhibitor shows promise in Parkinson’s

BioWorld Science

Researchers from Changchun Genescience Pharmaceuticals Co. Ltd. described the discovery and preclinical profile of an NLRP3 inhibitor with favorable brain...

4D Nucleome opens new wave of gene regulation research, discovery

BioWorld

After a decade of research, the NIH 4D Nucleome program on July 23 delivered a wealth of new insights into how spatial changes in chromatin structure and DNA...

Daybu readthrough in EU? Zevra’s NPC bid flounders

BioWorld

Zevra Therapeutics Inc. will try to follow in the footsteps of Acadia Pharmaceuticals Inc. with Rett syndrome drug Daybu (trofinetide) by asking the EMA’s...

Transcripta Bio raises funding to advance neuro pipeline

BioWorld Science

Transcripta Bio Inc. has raised $24 million since its series A to fund IND-enabling studies across its portfolio and support clinical preparation in its autism...